Multiple Eruptive Sebaceous Hyperplasia Secondary to Cyclosporin in a Patient with Bone Marrow Transplantation

Begonia Cortés, Gürkan Kaya
Division of Dermatology and Venereology, University Hospital of Geneva, Geneva, Switzerland

Keywords
Sebaceous hyperplasia · Cyclosporin · Bone marrow transplant · Graft · Transplantation · Face

Abstract
Many cutaneous complications have been described in patients treated with cyclosporin. Alterations of the pilosebaceous unit such as hypertrichosis are particularly frequent. However, the occurrence of sebaceous hyperplasia is exceptional. These lesions seem to be specific to cyclosporin rather than secondary to immunosuppression. Here, we report an exceptional case of eruptive multiple sebaceous hyperplasia secondary to cyclosporin treatment in a bone marrow transplant recipient only a few months after starting immunosuppressive treatment with cyclosporin.

Introduction
Sebaceous hyperplasia (SH) is a benign proliferation of the sebaceous glands, which in most cases is idiopathic and affects elderly patients. SH results from intrinsic, genetically determined (chronological) aging and extrinsic environmental photoaging. Moreover, this affection can arise in the setting of genetic diseases such as Muir-Torre syndrome or familial SH. Some data reported in the literature suggest that cyclosporin could also be a causative factor [1]. We report an unusual case of eruptive multiple SH secondary to cyclosporin treatment in a bone marrow transplant recipient.
Case Report

A 69-year-old male with a diagnosis of acute myeloid leukemia received allogenic bone marrow transplantation in May 2014, after immunosuppressive treatment with high doses of chemotherapy and lymphoid and total body irradiation. Five months later, high doses of corticosteroids were introduced for an acute cutaneous graft-versus-host disease. After reducing the dosage of steroids, lichenoid lesions of the skin and oral mucosa consistent with a chronic graft-versus-host disease appeared. A treatment of cyclosporin 350 mg/day (4.4 mg/kg) was initiated in December 2014, and the patient was then referred to our department to start extracorporeal photopheresis. Seven months later, he presented with multiple asymptomatic, skin-colored, 1- to 3-mm papules disseminated over the face and neck (Fig. 1). A skin biopsy of 1 of these lesions was performed. Histopathologic examination was consistent with SH with a cystic dilatation of the sebaceous duct (Fig. 2).

Discussion

Cyclosporin is an immunosuppressive drug that has been associated with several cutaneous adverse effects. These include tumoral lesions such as basal cell carcinoma and squamous cell carcinoma, which result from immunosuppression. Changes of the hair follicle specific to cyclosporin have also been observed. The most frequent manifestation is hypertrichosis, present in up to 60% of the patients. Other alterations of the pilosebaceous follicle include keratosis pilaris, acne, epidermal cysts, and folliculitis [2].

A few studies suggest that SH can also be a cutaneous manifestation specific to cyclosporin. SH was noted in 16 out of a total of 104 (16%) heart transplant recipients. The condition occurred only in males and exclusively affected the face. The mean age of the patients with SH was 54 years [3]. Among kidney transplant recipients, 7 out of 67 (10%) patients were reported to develop SH in another study. All of these patients were taking cyclosporin [2]. A few cases of disseminated SH secondary to cyclosporin therapy have been reported, among which there were 9 renal and 1 liver transplant recipients [4–9]. SH has been described in only 1 other bone marrow transplant recipient [10].

The development of benign and malignant cutaneous lesions in cyclosporin-treated transplant recipients is considered to be dose and duration dependent. In the majority of
cases, SH also occurs after many years of high-dose immunosuppressive therapy [6]. This contrasts with our patient who developed SH only a few months after starting cyclosporin treatment.

SH has not been observed in children, a fact that can be explained by the immaturity of the pilosebaceous unit in childhood [1]. Other immunosuppressive drugs have not been reported to induce SH in transplant recipients. This suggests that SH under cyclosporin is a direct and causal effect of this treatment on the sebaceous gland rather than a result of immunosuppression. Since cyclosporin is highly lipophilic, it has been suggested that the sebaceous gland might be the major cutaneous site of its elimination [4]. On the other hand, cyclosporine increases the activity of the 5-α reductase enzyme, increasing sebaceous secretion. This could exert an occlusive follicular action and play a role in the pathogenesis of adnexal lesions [10].

The fact that only males are affected suggests a genetic basis. Treatment with immunosuppressive drugs may unmask latent Muir-Torre syndrome or promote tumor progression in genetically susceptible patients, leading to the development of SH.

Although the lesions are benign, they may have major cosmetic and psychological effects on the patients because they are located mainly in the facial region. Pulsed dye laser or carbon dioxide laser have been described to be a successful treatment of disseminated SH, without recurrence after 6 months of follow-up despite continuation with cyclosporin treatment [8]. Isotretinoin inhibits sebaceous secretion and reduces the volume of the sebaceous gland. Some authors reported a good response to this molecule (10–20 mg/day) in renal transplant patients. After a few months of treatment, the lesions had almost completely disappeared. Nevertheless, patients had to be maintained on isotretinoin, as recurrence was common after the treatment had been stopped [3, 7, 9]. Other options include electrodesiccation, shave excision, and photodynamic therapy [11].

**Conclusion**

In conclusion, SH is a cutaneous lesion that should be added to the possible rare but specific pilosebaceous changes occurring during cyclosporin treatment. Our case is exceptional because of the extension and the rapid development of the lesions. Moreover, these lesions are essentially described in renal transplant recipients. To our knowledge, this is only the second case of disseminated SH observed after bone marrow transplantation [10].
Statement of Ethics

The patient gave his informed consent for the publication of this work.

Disclosure Statement

The authors have no conflicts of interest to disclose.

References